Name: The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023
Uploaded: 2022-12-20T11:13:15.016871+00:00
Duration: 1238 s
Channel: Vox Markets
Description: The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/613/005613/video_OmqzTIN.mp4#t=823

Vox Markets

The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023

Stated milestones hit throughout a year of major newsflow for the company, and strengthening the team to advance business development and clinical studies

Describing the unique “capital light” business model and its advantages

The use of artificial intelligence in the drug discovery process, deals signed with AI partners, and upcoming milestones for AI analysis

Progress of POLB 001, including the completion of its human challenge study without serious adverse events and aims to be partner-ready in 2023

What’s next on the road to POLB 001 commercialisation

Progress on other drugs in the pipeline, POLB 002 and POLB 003

Balance sheet strength supporting programmes through to commercialisation

Seeking out further potential drug candidates

Vox Markets talks to Jeremy Skillington, chief executive of infectious disease specialist Poolbeg Pharma, about a year which has seen its drug development programmes moving forward at pace thanks to its unique capital-light and AI led approach to R&D.

0:47 Stated milestones hit throughout a year of major newsflow for the company, and strengthening the team to advance business development and clinical studies
2:51 Describing the unique “capital light” business model and its advantages
4:07 The use of artificial intelligence in the drug discovery process, deals signed with AI partners, and upcoming milestones for AI analysis
9:06 Progress of POLB 001, including the completion of its human challenge study without serious adverse events and aims to be partner-ready in 2023
10:54 What’s next on the road to POLB 001 commercialisation
12:02 The renewed focus on infectious diseases, and government support for infectious disease drug development as part of pandemic preparedness plans
13:43 The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023
16:24 Progress on other drugs in the pipeline, POLB 002 and POLB 003 
18:09 Balance sheet strength supporting programmes through to commercialisation
19:01 Seeking out further potential drug candidates

Vox Markets talks to Jeremy Skillington, chief executive of infectious disease specialist Poolbeg Pharma, about a year which has seen its drug development programmes moving forward at pace thanks to its unique capital-light and AI led approach to R&amp;D.0:47 Stated milestones hit throughout a year of major newsflow for the company, and strengthening the team to advance business development and clinical studies 2:51 Describing the unique “capital light” business model and its advantages 4:07 The use of artificial intelligence in the drug discovery process, deals signed with AI partners, and upcoming milestones for AI analysis 9:06 Progress of POLB 001, including the completion of its human challenge study without serious adverse events and aims to be partner-ready in 2023 10:54 What’s next on the road to POLB 001 commercialisation 12:02 The renewed focus on infectious diseases, and government support for infectious disease drug development as part of pandemic preparedness plans 13:43 The advantages of orally delivered vaccines, Poolbeg’s collaboration with encapsulation specialist AnaBio on obesity and diabetes treatments, and plans for an exploratory trial in 2023 16:24 Progress on other drugs in the pipeline, POLB 002 and POLB 003 18:09 Balance sheet strength supporting programmes through to commercialisation 19:01 Seeking out further potential drug candidates

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/613/005613/video_OmqzTIN.mp4